Mukul Agarwal

Chief Business Officer at ReCode Therapeutics

Mukul Agarwal

Mukul Agarwal

Chief Business Officer at ReCode Therapeutics

Overview
RelSci Relationships

170

Contact Data
Trying to get in touch with Mukul Agarwal? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Mukul Agarwal likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer & President at ReCode Therapeutics

Relationship likelihood: Strong

Co-Founder & Director of Biology at ReCode Therapeutics

Relationship likelihood: Strong

Senior Vice President, Chemistry, Manufacturing & Controls at ReCode Therapeutics

Relationship likelihood: Average

Senior Vice President, Research & Development at ReCode Therapeutics

Relationship likelihood: Average

President, Chief Executive Officer & Director at Taysha Gene Therapies

Relationship likelihood: Average

Managing Director at Precision BioVentures LLC

Relationship likelihood: Average

Managing Director at Vida Ventures LLC

Relationship likelihood: Average

Co-Founder, Director at Cleave Therapeutics, Inc.

Relationship likelihood: Average

Senior Vice President, Clinical Development at Revance Therapeutics, Inc.

Relationship likelihood: Average

Senior Vice President, Technical Operations at Revance Therapeutics, Inc.

Relationship likelihood: Average

Paths to Mukul Agarwal
Potential Connections via
Relationship Science
You
Mukul Agarwal
Chief Business Officer at ReCode Therapeutics
Education

Carnegie Mellon University challenges the curious and passionate to imagine and deliver work that matters. A private, global research university, Carnegie Mellon stands among the world's most renowned educational institutions, and sets its own course.With cutting-edge brain science, path-breaking performances, innovative start-ups, driverless cars, big data, big ambitions, Nobel and Turing prizes, hands-on learning, and a whole lot of robots, CMU doesn't imagine the future, they create it.

The Ohio State University, commonly referred to as Ohio State or OSU, is a public research university in Columbus, Ohio. Founded in 1870, as a land-grant university and ninth university in Ohio with the Morrill Act of 1862, the university was originally known as the Ohio Agricultural and Mechanical College.

Vision: To contribute to India and the World through excellence in scientific and technical education and research; to serve as a valuable resource for industry and society; and remain a source of pride for all Indians. Mission: To generate new knowledge by engaging in cutting-edge research and to promote academic growth by offering state-of-the-art undergraduate, postgraduate and doctoral programmes. To identify, based on an informed perception of Indian, regional and global needs, areas of specialization upon which the institute can concentrate. To undertake collaborative projects which offer opportunities for long-term interaction with academia and industry. To develop human potential to its fullest extent so that intellectually capable and imaginatively gifted leaders can emerge in a range of professions. Values: Academic integrity and accountability. Respect and tolerance for the views of every individual. Attention to issues of national relevance as well as of global concern. Breadth of understanding, including knowledge of the human sciences. Appreciation of intellectual excellence and creativity. An unfettered spirit of exploration, rationality and enterprise.

Career History
Chief Business Officer
2020 - Current

ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of Cystic Fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and develop first-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations.

Vice President, Business Development
2016 - 2019

Revance Therapeutics, Inc. is a clinical stage biotechnology company. It engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.

Senior Director-Corporate Development & Strategy
Prior

Anacor Pharmaceuticals, Inc. develops medical solutions. The firm operates as a biopharmaceutical company, which focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company was founded by Lucy Shapiro, Stephen J. Benkovic, and David P. Perry in 2000 and is headquartered in Palo Alto, CA.

Other Affiliations
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Mukul Agarwal. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Mukul Agarwal's profile does not indicate a business or promotional relationship of any kind between RelSci and Mukul Agarwal.